CompletedPhase 4

Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women

South Korea149 participantsStarted 2023-01-03

Plain-language summary

To evaluate the effect of 1 year of risedronate treatment on the prevention of bone loss after denosumab discontinuation in denosumab-treated post-menopausal osteoporosis for a year

Who can participate

Age range50 Years – 80 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Postmenopausal women
✓. Patients diagnosed with postmenopausal osteoporosis and administered denosumab for 1 year

Exclusion criteria

✕. Any contraindication to risedronate
✕. Those evaluated as inappropriate at the discretion of the investigator

What they're measuring

Percent change from baseline in lumbar spine bone mineral density (LS BMD) at 1 year (%)

Timeframe: 1 year

Trial details

NCT IDNCT05630768

SponsorDong-A ST Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-07-23

View on ClinicalTrials.gov More Postmenopausal Osteoporosis trials